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Receptorscay accelerating factor (DAF) as a cell surface receptor. However, most of them
require additional cell surface coreceptors. We investigated the respective roles of DAF and class I human
leukocyte antigen (HLA) molecules in the early steps of the echovirus 11 (EV11) lifecycle in
rhabdomyosarcoma (RD) cells. EV11 infection was inhibited at an early stage by anti-β2-microglobulin
(β2m) and anti-HLA monoclonal antibodies and by a soluble monochain HLA class I molecule. Expression of
class I HLA molecules restored the early steps of the EV11 lifecycle, but its expression was not sufﬁcient for
EV11 replication and particle production. Expression of HLA class I molecules was associated with leukocyte
cell line permissiveness to EV11 infection. In conclusion, HLA class I molecules are involved in the early steps
of EV11 infection of RD cells and appear to participate in a complex interplay of surface molecules acting as
coreceptors, including DAF.
© 2008 Elsevier Inc. All rights reserved.Introduction
Echoviruses are small, non-enveloped, single-positive-stranded
RNA viruses belonging to the Picornaviridae family, genus Enterovirus.
They are associated with a broad spectrum of clinical manifestations,
ranging from non-speciﬁc illnesses to systemic disorders; they can
also cause meningitis, encephalitis and severe systemic infections in
neonates (Melnick, 1996; Pallansch and Roos, 2001). Most cases are
sporadic, but certain serotypes have been associated with outbreaks
(Kopecka et al., 1995; Mullins et al., 2004). Echovirus 11 (EV11) is one
of the most commonly isolated enterovirus serotypes (Oberste et al.,
2003). It is associated with various illnesses, including meningitis,
uveitis, and severe multisystem haemorrhagic diseases in neonates
and infants (El-Sageyer et al., 1998; Lukashev et al., 2003).
At least ten different picornavirus receptors have been identiﬁed
(Bergelson et al., 1992, 1993; Berinstein et al., 1995; Greve et al., 1989;
Goodfellow et al., 2001; Neff et al., 1998; Newcombe et al., 2003, 2004;
Roivainen et al., 1994; Shafren et al., 1997a,b; Williams et al., 2004;nter for Viral Hepatitis B, C and
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l rights reserved.Zautner et al., 2003, 2006). Many enteroviruses use decay accelerating
factor (DAF or CD55) as a cell surface receptor (Clarkson et al., 1995;
Karnauchowet al.,1996; Powell et al.,1998; Shafrenet al.,1995; Shafren
et al., 1997a). DAF is a 70-kDa glycophosphatidylinositol (GPI) anchor
protein with four extracellular short consensus repeat (SCR) domains
and a C-terminal serine/threonine-rich region and protects the serum
exposed cells from complement-mediated lysis (Lublin and Atkinson,
1989). Previous genetic and biochemical studies of enterovirus binding
to DAF have shown that enteroviruses can be divided into two major
groups according to the involved SCR binding domain. With the
exception of Coxsackie virus (CAV) 21 and enterovirus 70, which bind
SCR1, enteroviruses bind SCR3, with additional binding to SCR4 and
sometimes SCR2 (Bergelson et al.,1994; Karnauchowet al.,1996; Lea et
al., 1998; Pettigrew et al., 2006; Powell et al., 1998; Shafren et al., 1995;
Ward et al., 1994). Anti-DAF mAbs directed against SCR3 have been
shownto inhibit the infectionofhumanembryonic rhabdomyosarcoma
(RD) cells by several echovirus strains, including EV7 and EV11
(Bergelson et al.,1994;Ward et al.,1994).
Cell-surface coreceptors or accessory molecules in addition to DAF
may be needed by some echoviruses to induce the formation of A-
particles (sedimentation coefﬁcient 135S), the product of receptor-
mediated conformational changes in the native infectious virion
structure (sedimentation coefﬁcient 160S) (Pasch et al., 1999; Powell
et al., 1998; Shafren et al., 1997a,b). For instance, soluble DAF (sDAF)
blocks EV7 binding through steric hindrance. The interaction between
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particles (Powell et al., 1997). In contrast, the interaction of human
rhinovirus 14 and the soluble form of its receptor (intercellular
adhesion molecule-1: ICAM-1) or of poliovirus and the soluble
poliovirus receptor (PVR, CD155) induces irreversible conformational
changes leading to the formation of A-particles, suggesting that these
viruses do not need additional determinants at the cell surface
(Casasnovas and Springer, 1994; Gomez Yafal et al., 1993).
Recent reports have suggested that β2-microglobulin (β2m) and
CD59 — a GPI-anchored protein that regulates the complement
cascade at a later stage than DAF—may also play a role as a coreceptor
in the infectious cycle of EV7 (Goodfellow et al., 2000; Ward et al.,
1998). However, there is no direct evidence that β2m or CD59 is
involved in virus infection or A-particle formation. In addition, the
class I human leukocyte antigen (HLA) molecules, and particularly the
β2m light chain of the molecule, have also been shown to play a
signiﬁcant role in CAV9 internalization (Triantaﬁlou et al., 1999, 2002).
EV11 is genetically related to EV7 and CAV9 (Huttunen et al., 1996).
Some EV11 strains have been shown to recognize DAF as a receptor on
RD cells. However, other surface molecules can be used in cell lines
where DAF expression is reduced. This change in receptor use is
generally associated with a few amino acid changes in the capsid
protein sequence (Kim and Racaniello, 2007; Schmidtke et al., 2000;
Stuart et al., 2002b). Infection of RD cells by EV11 is also inhibited by
anti-β2m antibodies, with no blockade of virus binding or of
translation and replication of transfected viral RNA, arguing against
a physical association between EV11 and β2m (Ward et al., 1998).
Although the panspeciﬁc anti-HLA-A, -B, and -C monoclonal anti-
body (mAb) W6/32 has no effect on EV infection (Ward et al., 1998),
a role of class I HLA molecules in EV11 attachment and/or entry
cannot be ruled out.
The goal of this study was to examine the respective roles of DAF
and class I HLA molecules in the early steps of the EV11 lifecycle in RD
cells. We show that the DAF molecule is not systematically involved in
EV11 attachment to the surface of RD cells, and report a previously
unknown interaction of EV11 with class I HLA molecules.
Results
EV11 infection of RD cells is inhibited by an anti-β2m monoclonal
antibody and by the anti-HLA monoclonal antibody B9.12.1
We assessed the capacity of monoclonal antibodies directed
against DAF (mAb BRIC216), β2m (mAb MCA1115) and the HLA class
I heavy chain (mAbs W6/32, B9.12.1 and B1.23.2) to inhibit RD cell
infection by EV11 strains, including the reference prototype strain
Gregory and a clinical isolate of EV11 (HU-1108/89) responsible for a
severe epidemic in Hungary (Chevaliez et al., 2004; El-Sageyer et al.,
1998). The PV1/Mahoney strain, which recognizes a well-character-
ized receptor molecule (CD155) (Mendelsohn et al., 1989), was used as
a control, along with EV7 (Wallace strain), for which RD cell infection
is inhibited by anti-DAF and anti-β2 mAbs. The results are shown in
Figs. 1a–d.
As expected, poliovirus type 1 (PV1/Mahoney) infection of RD cells
was not inhibited by any of the antibodies tested (Fig. 1d), whereas
EV7 lytic infection of RD cells was efﬁciently inhibited by the anti-DAF
BRIC216 and anti-β2m MCA1115 mAbs (Fig. 1c). In contrast, anti-DAF
mAb BRIC216 had no effect on EV11 lytic infection, even at the highest
concentration used (40 μg/ml) and whatever the EV11 strain (Figs. 1a
and b). As shown in Figs. 1a and b, EV11 lytic infection of RD cells was
inhibited by the anti-β2mmAbMCA1115 and by one of the three anti-
HLA mAbs, B9.12.1. These two mAbs also inhibited EV7 infection (Fig.
1c). In order to rule out the role of a contaminant present in the
hybridoma cell supernatant containing B9.12.1mAb, the same experi-
ments were carried out with a puriﬁed IgG fraction of this mAb
derived from a different batch of hybridoma supernatant. The puriﬁedB9.12.1 mAb inhibited lytic infection of RD cells by both HU-1108/89
and Gregory EV11 strains (Figs. 1a and b). RD cell infection by two
other EV11 strains, RO-91/91 and FI-06666/89, isolated from clinical
and environmental samples, respectively, was also inhibited by mAb
B9.12.1 (data not shown).
We investigatedwhether the anti-β2mmAbMCA1115 and the anti-
HLA mAb B9.12.1 functioned additively or synergistically by assessing
the inhibitory effects of various doses of a combination of these two
antibodies on EV11 (HU-1108/89) infection (Fig. 1e). These antibodies
were found to inhibit EV11-mediated cell lysis synergistically.
EV11 infection of RD cells is inhibited by a soluble β2m-HLA-A⁎2
monochain
We then tested the ability of increasing concentrations of a
recombinant soluble β2m-HLA-A⁎2 monochain (human β2m fused
with the HLA-A⁎2 molecule (Lone et al., 1998; Motta et al., 1998) to
inhibit EV11 infection of RD cells. A membranous version of this
monochain was shown to efﬁciently present peptide antigens on
rodent cells to human cytotoxic T cells (Firat et al., 2001; Pascolo et al.,
1997; Snyder et al., 2004). As shown in Fig. 2, concentration-
dependent neutralization of RD cell infection was observed 3 h post-
infection. In contrast, soluble β2m-HLA-A⁎2 monochain did not affect
viral infection by the control strain PV1/Mahoney (data not shown).
Inhibition of EV11 infection of RD cells by the anti-HLA mAb B9.12.1
occurs at an early stage
We studied the effect of the anti-HLA mAb B9.12.1 and the anti-
β2m mAb MCA1115 added at various times before, concomitantly
with, or after EV11 infection of RD cells on the level of viral
multiplication (Fig. 3). Intracellular production of viral RNA was
assessed 5 h after infection. Maximum inhibition of infection was
observed when RD cells were incubated with these antibodies 30 to
60 min before infection (viral RNA reduction: 57% and 90% relative to
untreated cells, respectively) (Figs. 3a and b). Adding the antibodies at
the time of infection inhibited viral replication to a lesser extent (49%
and 62%, respectively). Finally, no effect on replication was observed
when the antibodies were added 30 to 120min after infection (Figs. 3a
and b). Viral RNA reduction was greater with anti-β2mmAb MCA1115
than with anti-HLA mAb B9.12.1, a ﬁnding in keeping with the strong
inhibitory effect of anti-β2mmAb observed for EV11 infection in Fig. 1.
We then transfected RD cells with puriﬁed EV11 HU-1108/89 and
PV1/Mahoney (negative control strain) viral RNAs after treatment
with anti-DAF, anti-β2m and anti-HLA B9.12.1, B1.23.2 monoclonal
antibodies and immunoglobulin isotypes were used as controls. With
both viral RNAs transfected, the viral titers measured 5 h after
transfection were not lower with mAb B9.12.1 and all other mAb
tested thanwith the control antibodies (Figs. 4a and b). This suggested
that mAb B9.12.1 does not act in the late stages of infection and that
mAb B9.12.1 binding to the cell surface does not alter the cell
machinery by interacting with virus-speciﬁc mechanisms. Overall,
these ﬁndings, togetherwith the observation that EV11 infection of RD
cells was inhibited by soluble HLA monochain, suggested that the
blocking effect of anti-HLA mAbs on EV11 HU-1108/89 infection
occurred at an early step of the viral lifecycle.
Anti-HLA mAb B9.12.1, but not anti-β2m mAb MCA1115, inhibits EV11
binding to RD cells; interference with A-particle formation
We assessed the ability of anti-β2m and anti-HLA mAbs to inhibit
the binding of EV11 (HU-1108/89) to RD cells. Anti-DAF mAb and the
EV7/Wallace and PV1/Mahoney strains were used as controls. The
effect of mAbs on binding was assessed by means of an antibody-
binding assay using radiolabeled virus (Fig. 5). The binding of
radiolabeled EV11 (HU-1108/89) to RD cells was inhibited by 36% by
Fig. 1. Concentration-dependent inhibition of enterovirus infection of RD cells by monoclonal antibodies. (a to d) RD cell monolayers were incubated with ﬁxed concentrations of
anti-DAF (BRIC216), anti-HLA (W6/32, B9.12.1 from hybridoma supernatant (1) and puriﬁed IgG (2) and B1.23.2), and anti-β2m (MCA1115) mAbs and mouse IgG (control) for 1 h at
37 °C. RD cells were then challenged with serial dilutions of stocks of EV11 (HU-1108/89) (a), EV11 (Gregory) (b), EV7 (Wallace) (c) and PV1 (Mahoney) (d), and stained after 40 h of
incubation. (e) RD cell monolayers were incubated with various concentrations of anti-β2m mAb MCA1115, alone or together with various concentrations of anti-HLA mAb B9.12.1.
Cells were challenged by incubation for 40 h with 103 PFU of EV11 (HU-1108/89) per well. Cell survival was estimated by staining with crystal violet-ethanol solution and reading
absorbance at 560 nm. An arbitrary value of 100 was attributed to the mean result of quadruple experiments performed in the absence of antibodies. The results of the experiments
performed in the presence of antibodies are expressed as mean (±SD) values relative to 100.
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MCA1115 nor anti-DAFmAb BRIC216 affected EV11 binding to RD cells.
Anti-β2m mAb did not increase the inhibitory effect of anti-HLA mAb
B9.12.1 on EV11 binding (Fig. 5a). Other anti-HLA mAbs (B1.23.2 and
W6/32) had no effect on EV11 binding (data not shown). Neither anti-
HLA mAb B9.12.1 nor anti-β2m mAb MCA1115 affected the binding of
radiolabeled EV7, whereas anti-DAF mAb BRIC216 totally inhibited
EV7 binding, as already reported (Clarkson et al., 1995; Ward et al.,
1994) (Fig. 5b). None of the antibodies tested affected the binding of
radiolabeled PV1, the negative control (Fig. 5c).
We investigated themechanism by which the anti-HLAmAb B9.12.1
and the anti-β2m mAb MCA1115 blocked EV11 and EV7 infections, bystudying A-particle formation in the presence of mAbs during the
binding and/or decapsidation phase. Radiolabeled EV11 (HU-1108/89)
and EV7 (Wallace) was bound to RD cells at 4 °C before incubating the
cells at 37 °C for 30 min or 2 h with these mAbs, respectively. Cell-
associated and eluted viruses were measured by means of sucrose
gradient sedimentation (Fig. 6). As shown in Figs. 6a and 6b, in the
absenceof antibody, cell-associated andeluted radioactivity of EV11was
detected in160S,135S and80Sparticles. Small amountof 80Sparticles in
the cell supernatant indicates that these particles have been detached
from the surface or released from the cells. In the presence of mAb
B9.12.1 during the binding phase at 4 °C and the internalization phase at
37 °C, cell-associated EV11 particles and subparticles were not detected
Fig. 2. Effect of increasing concentrations of the soluble monochain class I HLAmolecule
β2m-HLA-A⁎2 on EV11 infection of RD cells. The results are shown as the reduction in
EV11 RNA, measured by means of quantitative real-time PCR, relative to the control
experiment without soluble monochain. Total cellular EV11 RNA is shown in gray at the
time of infection, and in black 3 h post-infection.
Fig. 4. Infectivity of the viral RNA in the presence of anti-DAF SCR3 (BRIC216), anti-β2m
(MCA1115), anti-HLA-A, -B, and -C (B9. 12. 1 and B1. 23. 2), isotype control (IgG mouse)
or negative controls (PBS 0.09% NaN3, glycine 0.1 M pH7). RD cell monolayers were
incubated in the presence of anti-DAF (40 μg/mL), anti-β2m (5 μg/mL), anti-HLA-A, -B,
and -C (1:100), IgG mouse (40 μg/mL) or the absence of antibodies (PBS 0.09% NaN3,
glycine 0.1 M pH7) for 1 h at 37 °C. The cells were then transfected with 1 μg of puriﬁed
viral EV11 (HU-1108/89) RNA (a) or puriﬁed viral PV1/Mahoney (b) using Effectene®
reagent and the infection was allowed to proceed for 5 h at 37 °C in 5% CO2. The
infectivity of each sample was assessed by plaque assay on RD cells and the results
were expressed in number of PFU per μg of viral RNA±SD. Pretreatment with RNAse
(100 μg/mL) abolished infectivity.
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(Fig. 6a, gray line). In contrast, anti-β2mMCA1115mAbdidnot appear to
inhibit EV11 binding, whereas they appeared to slightly affect
subparticle formation. Analysis of eluted viral particles detached from
the cell surface in the presence of bothmAbs showed that far fewer 135S
particles were detected (Fig. 6b). In contrast with EV11, anti-HLA B9.12.1
and anti-β2m MCA1115 mAbs appeared to affect EV7 subparticle
formation but were not able to inhibit its binding (Figs. 6c and d).
In order to study the inﬂuence of anti-HLA mAb B9.12.1 and anti-
β2m mAb MCA1115 on A-particle formation, independently of their
inhibition of cell binding, RD cells bound at 4 °C with radiolabeled
EV11 (HU-1108/89) or EV7 (Wallace) were incubated with the two
mAbs alone at 37 °C for 30 min or 2 h, respectively. The production of
135S particles was slightly reduced when the cells were treated with
anti-HLA mAb B9.12.1 and, to a lesser extent, with anti-β2m
MCA1115 mAb, suggesting that these antibodies directly or indirectly
interfere with A-particle formation (data not shown). Anti-DAF mAb
BRIC216 had no effect on A-particle formation (data not shown).
Class I HLA molecules and DAF contribute to EV11 binding in transfected
CHO cells
We investigated the role of human DAF and HLA molecules in
the binding of EV11, by stable transfection of CHO cells expressing
human DAF (CHO-DAF/A9) (Clarkson et al., 1995; Coyne et al.,Fig. 3. Effect of the time of mAb treatment on RD cell infection by EV11. RD cell monolayers w
before, concomitantly with, and after EV11 infection. The letter C corresponds to control with
5 h after infection. Results are expressed as means of two independent experiments±SD in1992) with a plasmid encoding a membranous version of the
β2m-HLA-A⁎2 monochain (see Materials and methods). Flow
cytometry showed correct expression of both DAF and β2m-HLA-
A⁎2 on the transfected CHO cells (CHO-DAF-β2m-HLA-A⁎2) (data
not shown).
Surprisingly, CHO-DAF/A9 cells expressing only DAF bound radi-
olabeled EV11 (HU-1108/89) and this binding was totally inhibited byere treated with ﬁxed concentrations B9.12.1 (a) or MCA1115 (b) mAbs at various times
out mAb at 120 min. Viral RNAwas quantiﬁed by reverse-transcriptase quantitative PCR
μg relative to the standard EV11 dilution panel used for calibration.
Fig. 5. Inhibition of enterovirus binding to RD cells. RD cell monolayers were incubated
with anti-DAF (BRIC216), anti-β2m (MCA1115), and anti-HLA (B9.12.1) mAbs, control
isotypes (IgG1κ, IgG2aκ) or DMEM. Cells were then incubated with radiolabeled EV11
(HU-1108/89) (a), EV7 (Wallace) (b) and PV1 (Mahoney) (c). Bound radiolabeled virus
levels were determined by liquid scintillation counting. Results are expressed as the
means of two experiments±SD.
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CHO/Bill, a DAF-deﬁcient cell line, is not able to bind a large quantity of
radiolabeled EV11 and this binding is not abrogated by an anti-DAFmAb
directed against SCR3 domain (Fig. 7c). Co-expression of β2m-HLA-A⁎2
was also associated with radiolabeled EV11 binding to CHO-DAF-β2m-
HLA-A⁎2 cells (Fig. 6a). Both anti-DAF mAb and anti-HLA mAb B9.12.1
inhibited EV11 binding to these CHO cells. However, inhibition was
stronger with anti-HLA mAb B9.12.1 than with anti-DAF mAb (73% vs
39%, respectively) (Fig. 6a). Used together, the two antibodies appeared
to have a partly additive inhibitory effect (90% of binding inhibition).
Altogether, these results suggest that, in contrast to RD cells, humanDAF
may be involved in EV11HU-1108/89 binding to the surface of CHO cells.
However, the stronger inhibition of binding with anti-HLA mAb B9.12.1
when β2m-HLA-A⁎2 was expressed suggests preferential use of surface
HLA molecules by EV11 in this model. This result conﬁrms the role of
HLA molecules in EV11 binding.Expression of both human DAF and class I HLA molecules is not sufﬁcient
for EV11 replication and particle production in CHO cells
As rodent cells expressing DAF and class I HLA bound EV11 HU-
1108/89 and formed A-particles (data not shown), we investigated
whether EV11 was able to replicate into the transfected CHO cells.
Conﬂuent monolayers of RD and CHO-DAF-β2m-HLA-A⁎2 cells were
infected with virus (1 to 50 PFU/cell). As expected, a complete
cytopathic effect was observed in RD cells 24 h after infection (data
not shown). In contrast, no cytopathic effect was seen in CHO-DAF-
β2m-HLA-A⁎2 cells and no viral increase was observed between 0 and
48 h after infection (data not shown).
We looked for intracellular viruses, 6 h after infection, using ﬂow
cytometry and a polyclonal rabbit anti-EV11/HU-1108/89 serum. We
also investigated whether the lack of viral multiplication was due to a
blockade late in the viral cycle by seeking for negative and positive
strands of intracellular viral RNA three and 6 h post-infection. EV11
virions and positive strands of intracellular viral RNA were detected
6 h post-infection in the cytoplasm of RD cells but not in CHO-DAF-
β2m-HLA-A⁎2 cells (data not shown) or other rodent cells (CHO/Bill,
CHO-DAF/A9, data not shown). Negative strands were only detected
3 h post-infection in the cytoplasm of RD cells (data not shown). Thus,
CHO cells expressing human DAF and monochain HLA molecules are
not permissive to EV11 infection. However, transfection of CHO-DAF-
β2m-HLA-A⁎2 cells with puriﬁed EV11 HU-1108/89 RNA led to
efﬁcient viral replication and abundant viral particle production
(data not shown). Moreover, following adsorption of radiolabeled
EV11 virions onto CHO-DAF-β2m-HLA-A⁎2 cells and incubation at
37 °C, 135S A-particles were detected associated with cells and free in
the supernatant (data not shown).
This suggests that the EV11 infection of CHO-DAF-β2m-HLA-A⁎2
cells is blocked in an early step of the viral cycle, between A-particles
formation and release of the viral genome in the infected cells.
Expression of HLA class I molecules, but not DAF, is associated with
leukocyte cell line permissiveness to EV11 infection
Daudi cells, Raji B cells and the monocytic cell line U-937 were
infected with EV11 (HU-1108/89). Daudi cells naturally express DAF,
Raji cells express class I HLA molecules and U-937 cells express both
molecules at their surface (Haddad et al., 2004; Nilsson et al. 1974;
Vuorinen et al., 1999). DAF and class I HLA molecule expression was
conﬁrmed in these cell lines by ﬂow cytometry with mAbs (Fig. 8c). As
shown in Fig. 8a, only Raji cells and U-937 cells, that both express class
I HLA molecules, produced EV11 viral particles in culture. In contrast,
Daudi cell infection did not lead to viral particle production, whereas
Daudi cell transfection with puriﬁed EV11 HU-1108/89 RNA led to
efﬁcient viral replication and abundant viral particle production (Fig.
8b). Although we cannot rule out that other factors between the two
cell lines could play a role, this result reinforces the implication of the
class I HLA molecules in infection by at least certain EV11 strains, via a
DAF-independent mechanism. Similar results were obtained when
leukocyte cell lines were infected with EV7 (Wallace). Only Raji and U-
937 cell lines are able to produce infectious viral EV7 particles,
suggesting that the only expression of DAFmolecule at the cell surface
is not sufﬁcient to supportive EV7 infection (Data not shown).
However, Raji cell line a DAF-deﬁcient cell line expression is able to
produce infectious virions, suggesting a DAF-independent mechanism
for EV7 viral entry in this speciﬁc cell line.
Discussion
Enterovirus entry into target cells is a complex, multistep process.
Cell attachment and internalization of several enterovirus serotypes
have been reported to involve different cell surface receptors and
mechanisms of entry, including internalization via clathrin-coated
Fig. 6. Sedimentation gradient analysis of viral and subviral particles formed in the presence of anti-β2m and anti-HLA mAbs. RD cell monolayers were incubated with radiolabeled
EV11 (HU-1108/89; MOI 50 PFU/cell) or EV7 (Wallace; MOI 50 PFU/cell) in the presence of the anti-β2mmAbMCA1115 (5 μg/ml) in black squares, or the anti-HLAmAb B9.12.1 (1:100)
in gray squares or in the presence of DMEMwithout mAb in empty circles. Unbound virus was removed and cells were incubated in the presence of the samemAbs or medium alone.
Cell-associated (a and c) and eluted (b and d) viral and subviral particles were separated by sucrose gradient centrifugation, then fractionated and quantiﬁed.
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and Wetz, 1990; Marjomaki et al., 2002; Powell et al., 1998; Roivainen
et al., 1996; Shafren et al., 1997a,b; Stuart et al., 2002a; Triantaﬁlou et
al., 1999). In the search for coreceptor molecules that could be
involved, together with DAF, in EV11 entry into cells, we investigated
the role of class I HLA molecules in RD cell infection by EV11. Indeed, a
role of β2-microglobulin in the infectious cycle of EV7 and other
echovirus serotypes has been suggested and our results conﬁrm that
β2-m is involved in later steps of the entry process (Ward et al., 1998).
Class I HLA molecules have been shown to play a role in post-binding
events of the CAV9 infectious cycle (Triantaﬁlou et al., 1999, 2002). In
the present study, our results strongly suggest a role for class I HLA
molecules in the early steps the EV11 life cycle, including attachment
and entry. Indeed, EV11 infection of RD cells was synergistically
inhibited by mAbs directed against the class I HLA heavy chain B9.12.1and human β2m. Moreover, we found that 135S A-particle production
was reduced when the cells were treated with anti-HLA mAb B9.12.1
and, to a lesser extent, with anti-β2mMCA1115mAb, pointing to a role
of HLA molecules in A-particle formation. In addition, we found that
Daudi cells, a β2m-deﬁcient B cell line (Klein et al., 1968), could not be
infected by EV11, whereas Raji cells, which express high levels of class
I HLA molecules at their surface, produced infectious viruses.
Although we cannot rule out that other factors between the two cell
lines could play a role, our results reinforce the hypothesis of an
implication of class I HLA molecules in certain EV11 strain infection.
Indeed, in contrast to CAV9 and EV7, class I HLA molecules play a
role in EV11 attachment to RD cells. This argues for a physical
association between EV11 and the heavy chain of class I HLA
molecules spanning the epitope recognized by mAb B9.12.1. However,
the blocking effect of B9.12.1 was partial in our experiments,
Fig. 7. Inhibition of enterovirus binding to CHO cells transfected with DAF (CHO-DAF/A9 cells) and β2m-HLA-A⁎2 (CHO-DAF-β2m-HLA-A⁎2 cells) or an empty vector (CHO/Bill cells).
(a) CHO-DAF-β2m-HLA-A⁎2 cells were incubated in the presence of anti-DAF (BRIC216), anti-β2m (MCA1115), and anti-HLA (B9.12.1) mAbs, control isotypes (IgG1κ, IgG2aκ) or
DMEM. (b) CHO-DAF/A9 cells and (c) CHO/Bill cells were incubated in the presence of anti-DAF (BRIC216) or control isotype (IgG1κ). Cells were then incubatedwith radiolabeled EV11
(HU-1108/89). Bound radiolabeled virus levels were determined by liquid scintillation counting. Results are expressed as the means of two experiments±SD.
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EV11 entry into RD cells or that the class I HLA molecule domain that
interacts with EV11 is only partially masked by mAb B9.12.1. In
addition, the data shown in Figs. 1 and 5, which suggest that anti-β2m
MCA1115 mAb inhibits EV11 cell cycle but not its binding, that mAb
B9.12.1 only partially inhibits EV11 binding but impairs infection, and
that both antibodies reduce EV7 infection while not affecting its
binding point to a role for these antibodies in host-binding events that
are important in the virus cell cycle. The later steps of the virus life
cycle were not studied in this work and the underlying mechanisms
remain to be determined.
Cross-inhibition studies have shown that mAbs B9.12.1, W6/32 and
B1.23.2 target different clusters of epitopes (Layet et al., 1984;
Malissen et al., 1982; Rebai and Malissen, 1983). This may explain
why only mAbs B9.12.1 is active against EV11 infection. The efﬁciency
of mAb inhibition of EV11 infection could also depend on the heavy
chain haplotype, which determines their ability to bind all or only
certain HLA molecules. Indeed, B9.12.1 is a panspeciﬁc mAb that
inhibits EV11 infection, whereas B1.23.2 recognizes only some of the
molecules forming complexes with β2m and does not inhibit EV11
infection (Rebai andMalissen,1983). However, this hypothesis is ruled
out by the fact thatW6/32, which recognizes all class I HLA-A, -B and -
C molecules independently of the haplotype, does not inhibit EV11
infection (Parham et al., 1979). This suggests that the ability of mAb
B9.12.1 to affect viral infection does not depend on a certain HLA-
haplotype, but on the generic HLA epitope this mAb binds to.
DAF has been reported to play a role within the receptor complex
for EV11 in several cell types (Powell et al., 1997; Stuart et al., 2002b).
Here we provide evidence that entry into RD cells of (at least some)
EV11 strains is a DAF-independent mechanism. Nevertheless, we
found that one of the EV11 isolates bound to DAF on CHO cells stably
transfected with the human DAF gene, probably in relation with a
large expression of human DAF on transfected cells. The difference
between CHO and RD cells could be explained by the different levels of
expression of DAF at the cell surface, as conﬁrmed by ﬂow cytometry
analysis in this study (data not shown). Most of the echovirus strains
that have been shown to use DAF as a receptor, including EV11 strains,
bind to the SCR3 domain (Lea et al., 1998). This ﬁnding conﬁrmed here
by the inhibition of EV11 binding to DAF-expressing CHO cells by an
anti-DAF mAb speciﬁc for the SCR3 domain. However, CAV21 bindsDAF via the SCR1 domain (Shafren et al., 1997a). Our experiments
showing the lack of inhibition of RD cell infection by anti-DAF mAb
directed against SCR3 raise the possibility that EV11 interacts with
domains of the DAF molecule not recognized by this mAb. Never-
theless, our ﬁndings showing that SCR3 is involved in RD cell infection
by other EV11 strains (Lea et al., 1998) points rather to strain-speciﬁc
differences. In addition, EV11 binding to CHO cells expressing DAF and
the HLA monochain was inhibited not only by the anti-DAF mAb, but
also and more importantly by the anti-HLA mAb B9.12.1, indicating
that both DAF and HLA could be involved in viral binding, depending
on the cellular context. Overall, the diversity of molecules and
mechanisms involved in enterovirus entry into host cells might
ensure optimal permissiveness to virus infection.
Although CHO cells were able to replicate and produce EV11 after
transfection with puriﬁed viral RNA, infection of rodent cells
expressing DAF and the HLA β2m-HLA-A⁎2 monochain led to A-
particle generation but not to a productive infection. We cannot rule
out that, although the chimeric HLA monochain has been shown to be
functional in terms of antigen presentation (Firat et al., 2001; Pascolo
et al., 1997; Snyder et al., 2004), it does not appear to be fully
functional for viral infection, in contrast with the natural class I HLA
molecules. It is likely that other cellular factors are required for EV11
to complete its replicative cycle in CHO cells.
Our experiments thus suggest that HLAmolecules are necessary but
not sufﬁcient to mediate EV11 entry into RD cells. Coreceptor molecules
or additional receptor molecules have been implicated in the entry of
other viruses that use HLA class I molecules. CAV9 uses integrin αvβ3
and GRP78 as receptor molecules, whereas class I HLA molecules are
only involved in the internalization step (Triantaﬁlou et al., 1999, 2002).
The role of integrins and GRP78 in EV11 infection remains to be tested.
Class I HLA heavy chain has been shown to act as a receptor for
adenovirus type5,with humanﬁbronectin type III acting as a coreceptor
(Hong et al., 1997). SV40 also binds Class I HLA molecules on the cell
surface, but a coreceptorappears tobeneeded too (Anderson et al.,1998;
Tsai et al., 2003). The othermolecules involved, togetherwith class I HLA
molecules, in the early steps of EV11 infection remain to be identiﬁed.
In conclusion, we showhere that HLA class Imolecules are involved
in the early steps of EV11 infection of RD cells. These molecules are
involved in viral attachment and might also play a role in A-particle
formation. HLAmolecules appear to participate in a complex interplay
Fig. 8. Echovirus replication in leukocytic cell lines. Suspension cultures of Daudi
(white), Raji (gray) and U-937 (black) cells were infected with EV11 (HU-1108/89) (a).
Daudi cells were also transfected with 1 μg of puriﬁed viral EV11 (HU-1108/89) RNA in
the absence or in the presence of RNAse (100 μg/mL) using Effectene® reagent and the
infection was allowed to proceed for 5 h at 37 °C in 5% CO2 (b). The infectivity of each
sample was assessed by plaque assay on RD cells and the results were expressed in
number of PFU per μg of viral RNA±SD. The infectious titers were determined by plaque
assay and are shown at the top. (c) Membrane expression of DAF and β2m-class I HLA
molecules measured by ﬂow cytometry is shown in the table at the bottom. The results
are expressed as a mean ﬂuorescence intensity (MFI) ratio calculated by dividing the
observed MFI in the presence of the antibody by the MFI in the negative control. A
ratio≥1.5 was considered positive.
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components and related pathways remain to be determined.
Materials and methods
Virus strains
All EV11 strains used in this study, including the prototype strain
Gregory, the clinical isolates HU-1108/89 and RO-91/91 and the
environmental isolate FI-06666/89 have been described elsewhere
(Chevaliez et al., 2004). In addition, control strains, including
echovirus 7 (Wallace) and poliovirus type 1 (Mahoney), were
propagated in RD and HEp-2C cells, respectively. Viral stocks were
titrated by plating appropriate dilutions of infected RD cells and
counting plaque-forming units (PFU).
Cell culture
RD and HEp-2C (human epidermoid larynx carcinoma) cells were
maintained in DMEM (Dulbecco's modiﬁed Eagle's medium) contain-ing 4.5 g/l glucose, 0.02 M tricine and 0.004 g/l D-biotin (BioMedia),
supplemented with 10% newborn calf serum (BioMedia). U-937
(human histiocytic lymphoma) cells, Daudi (human Burkitt lym-
phoma, β2m-deﬁcient) (Klein et al., 1968) and Raji (human Burkitt
lymphoma) cells were propagated as non-adherent stationary
cultures in RPMI 1640 medium (Life Technologies), containing
25 mM HEPES (Life Technologies) and supplemented with 10% fetal
calf serum (FCS) (BioMedia). Chinese hamster ovary (CHO) cell clones
stably transfectedwith the empty expression vector (CHO-Bill) or with
a plasmid expressing human DAF (CHO-DAF/A9) were obtained from
D.M. Lublin (Faculty of Medicine, Washington) (Clarkson et al., 1995;
Coyne et al., 1992). CHO cells were cultured in Ham's F-12 medium
(Life Technologies) supplemented with 10% FCS and 0.25 mg/mL
Geneticin (Life Technologies). Cells were cultured at 37 °C in an
atmosphere containing 5% CO2.
Antibodies
Monoclonal antibody (mAb) BRIC216 (IgG1κ), that recognizes the
SCR3 domain of DAF, was obtained from IBGRL and puriﬁed from
hybridoma culture supernatant by afﬁnity chromatography on
Protein A Sepharose (resuspended in 0.1 M glycine buffer pH7).
MAb MCA1115 (IgG1κ), that recognizes human β2m, was used after
isolation from tissue culture supernatant (Serotec) and puriﬁcation
by afﬁnity chromatography on Protein A Sepharose (resuspended in
PBS, 0.09% sodium azide (NaN3)). MAb W6/32 (IgG2aκ), that
recognizes a monomorphic epitope composed of the heavy chain
and β2m of class I HLA molecules (Parham et al., 1979), was
obtained from BIODESIGN following puriﬁcation from hybridoma
supernatant by afﬁnity chromatography on Protein A Sepharose
(resuspended in PBS, 1 mg/mL BSA, 10 mM NaN3). MAb B9.12.1, that
also binds class I HLA-A, HLA-B, and HLA-C molecules, and MAb
B1.23.2 (IgG2aκ), that recognizes HLA-A and HLA-B molecules
(Malissen et al., 1982; Rebai and Malissen, 1983), were recovered
from hybridoma supernatants without further puriﬁcation or were
obtained from BIODESIGN after puriﬁcation by ion-exchange
chromatography and resuspension in water. Polyclonal rabbit anti-
EV11/HU-1108/89 antibody was kindly provided by G. Berensci
(Department of Virology, “Bela Johan National” Center of Epidemiol-
ogy, Budapest, Hungary) (El-Sageyer et al., 1998). Anti-mouse and
anti-rabbit immunoglobulins conjugated to ﬂuorescein isothiocya-
nate (FITC) were obtained from Biorad. Puriﬁed immunoglobulin
isotype controls IgG1κ (MOPC-21) and IgG2aκ (UPC-10), recovered
from ascites, were purchased from Sigma. Puriﬁed mouse whole IgG
fraction was obtained from Pierce.
Puriﬁcation of the soluble monochain class I HLA molecule
β2m-HLA-A⁎2
We used a previously described supernatant of CHO cells
expressing the soluble recombinant monochain β2m-HLA-A⁎2 (SC-
A2) (Lone et al., 1998; Motta et al., 1998). Brieﬂy, an SC-A2 construct
was engineered by connecting the ﬁrst three domains of HLA-A⁎2
heavy chain to human β2m through a 15-amino-acid spacer and
transfected into CHO cells. Clones resistant to methotrexate were
selected and the level of the secreted soluble monochain was
monitored in the culture supernatant by ELISA in microtitration plates
coated with an appropriate monoclonal antibody (Abastado et al.,
1995; Lone et al., 1998). The recombinant soluble monochain was
puriﬁed from the supernatant of HLA-A⁎2 transfected cells by means
of afﬁnity chromatography using the anti-β2m mAb MCA1115,
concentrated by ultraﬁltration using Vivaspin centrifugal concentra-
tors (Sartorius AG, Goettingen, Germany) and eluted in PBS containing
protease inhibitors (Complete, Boerhinger-Mannheim, Mannheim,
Germany). The concentration of puriﬁed molecule β2m-HLA-A⁎2 in
the eluate was measured in mg/L by means of the N Latex β2-
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Virus blocking assays
96-well plates of RD cells at 80% conﬂuence were washed with
serum-free DMEM and then incubated with 50 μl of the anti-DAF mAb
BRIC216 (40 μg/mL), the anti-β2m mAb MCA1115 (5 μg/mL), the anti-
HLA mAbs (B9.12.1 from hybridoma supernatants (1:100) or puriﬁed
(10 μg/mL), B1.23.2 (1:100) or W6/32 (10 μg/mL)), or the negative
controls (mouse IgG fraction or DMEM) for 1 h at 37 °C. Cell
monolayers were then challenged with 100 μl of 10-fold serial
dilutions of viral stocks (108 PFU/mL) and the plates were incubated
at 37 °C for 40 h. Infected cell monolayers were stained with crystal
violet-ethanol solution. We also studied concentration-dependent
mAb blockade of EV11 infection in monolayers of RD cells in 96-well
plates previously incubated with the anti-β2m mAb MCA1115 at
concentrations of 0.16 to 5.00 μg/mL, alone or in combinationwith the
anti-HLA mAb B9.12.1 (hybridoma supernatant) at a dilution of 1:100,
1:500 or 1:1000. The plates were incubated for 1 h at 37 °C before
challenge with 103 PFU of EV11 (HU-1108/89) per well for 40 h at
37 °C. We quantiﬁed cell survival after infection by incubating
monolayers with crystal violet-ethanol solution, washing them with
distilled water and reading the plates at a wavelength of 560 nmwith
a 96-well plate reader. The experiments were run in quadriplicate and
the results are expressed as means±standard deviations (SD) of the
ratio of infected cell lysis relative to uninfected control cell
monolayers.
Assessment of mAb effect on EV11 genomic RNA production in infected
cells
RD cells were treated with the anti-β2m mAb MCA1115 (5 μg/mL)
or the anti-HLA mAb B9.12.1 (1:100) at various times before or after
infection with EV11 (HU-1108/89) at a multiplicity of infection (MOI)
of 1 PFU/cell in 12-well plates for 5 h at 37 °C. The cell monolayers
were then washed three times with PBS and total RNA was extracted.
RNA isolation and reverse transcription
Total RNA was extracted with the RNable reagent (Eurobio,
Montpellier, France), according to the manufacturer's instructions.
The RNA pellet was dissolved in 20 μl of DEPC-treated water
(Invitrogen, Carlsbad, California) and the absorbance of the resulting
solutionwas determined at 260 nm. RNAwas reverse transcribedwith
10 pmol of the previously described EUC2a primer (Caro et al., 2001).
The reactionmixture (20 μl) contained 50mM Tris–HCl pH 8.3, 75mM
KCl, 3 mM MgCl2, 10 mM dNTPs, 2 mM DTT, 20 U of ribonuclease
inhibitor (RNasin, Promega, Madison, Wisconsin) and 50 U of
Superscript II reverse transcriptase (Invitrogen). The reaction mixture
was incubated for 30 min at 50 °C and then for 5 min at 95 °C to
inactivate the enzyme. The cDNA products were puriﬁed with the
QIAquick PCR Puriﬁcation kit (Qiagen, Valencia, California) and eluted
in 50 μl of 10 mM Tris–Cl pH 8.5.
Real-time quantitative PCR
Primers speciﬁc for EV11 HU-1108/89 2A genomic region (5′-
CACAACGATTGGCAAAACTGTG-3′ and 5′-GAGGATGACGCGATG-
GAGCA-3′) were used to amplify a 376-bp DNA fragment. The PCR
mixture contained 5 μl each of the forward and reverse primers (ﬁnal
concentration 600 nM), 25 μl of 2X Real-time SYBR® Green I mix
(qPCRTMMastermix for SYBR® Green I, Eurogentec, Seraing, Belgium),
and 5 μl of cDNA. Real-time PCR was performed with an ABI Prism
7700 automatic sequencer (Applied Biosystems, Foster City, Califor-
nia), using universal cycling conditions (2min at 50 °C,10min at 95 °C,
40 cycles of 15 s at 95 °C and 1 min at 60 °C). Cycle threshold (CT)
values were determined by automatic threshold analysis with ABIPrism version 1.0 software. Dissociation curves were plotted and the
ampliﬁed products were visualized by electrophoresis in 2% agarose
gels. Quantiﬁcation was carried out by comparing the results with a
standard curve run in parallel, created with serial 10-fold dilutions of
EV11 viral RNA (EV11/HU-1108/89).
Virus puriﬁcation and RNA extraction
RD cells were infected at high multiplicity (25–50 PFU/cell) for
30 min at 37 °C. The cell monolayers were then incubated in DMEM
supplementedwith 2% FCS at 37 °C until complete cell destructionwas
observed (i.e. within 24–48 h). Cells were subjected to three freeze–
thaw cycles and cell debris was removed by centrifugation (12000 g,
30 min, 4 °C). The resulting viral suspensions were concentrated by
ultracentrifugation (150000 g, 3 h, 4 °C). Viral concentrates were
puriﬁed by centrifugation on a CsCl gradient (45% CsCl w/v in PBS), as
previously described (Blondel et al., 1983). Virus-containing fractions
were pooled and CsCl was eliminated on PD-10 columns (Pharmacia
Biotech, Uppsala, Sweden). RNA was extracted directly from puriﬁed
virus stocks by treatment with proteinase K (Eurobio) at a ﬁnal
concentration of 0.5 mg/mL for 15 min at 37 °C and 30 min at 50 °C,
followed by phenol–chloroform (v/v) extraction at 60 °C and ethanol
precipitation. The RNA pellet was dried and resuspended in DEPC-
treated water. Viral RNAwas quantiﬁed by UV spectrophotometry and
the quality of the RNA was checked by electrophoresis in agarose gel
containing formaldehyde (ﬁnal concentration 2.2 M).
Neutralization of EV11 infection with soluble monochain Class I HLA
molecule β2m-HLA-A⁎2
Soluble monochain Class I HLA molecule β2m-HLA-A⁎2 was made
up to volume at concentrations ranging from 2.5 μg/mL to 321.5 μg/mL
in PBS and incubated with 0.1 PFU of EV11 (HU-1108/89) or poliovirus
type 1 (PV1/Mahoney), used as negative control. β2m-HLA-A⁎2 was
then incubated at 37 °C for 1 h and applied to 96-well plates of RD cells
at 80% conﬂuence. The cells were incubated for 3 h at 37 °C. The
monolayers were then washed three times with PBS and total RNA
was extracted as previously described. For EV11 and poliovirus RNA
ampliﬁcation, reverse transcription followed by real-time quantitative
PCR were performed as described above. The amounts of viral RNA
were expressed in arbitrary units for the different concentrations of
β2m-HLA-A⁎2, at the time of infection and 3 h later, and were
compared to the negative control.
Transfection of RD cells with viral RNA
RD cell monolayers were incubated in 12-well plates with mAbs or
negative controls (PBS 0.09% NaN3 or glycine 0.1 M pH 7) for 1 h at
37 °C. The cells were then transfected with 1 μg of puriﬁed EV11 viral
RNA (HU-1108/89, FI-06666/89) or PV1/Mahoney viral RNA, by using
Effectene®, according to the manufacturer's instructions (Qiagen).
Viral RNA (1 μg) was mixed with Condensation Buffer (Buffer EC) and
Enhancer (1:8 ratio) for 5 min at room temperature. We then added
the Effectene® transfection reagent (1:10 ratio) and the RNA-
Effectene mixtures were incubated for 10 min at room temperature.
RD cells were washed once with serum-free DMEM. The cells were
then overlaid with the RNA-Effectene mixture in DMEM supplemen-
tedwith 2% FCS. Cells were incubated for 5 h at 37 °C in an atmosphere
containing 5% CO2. Supernatants and cells were harvested. Cells were
subjected to three freeze–thaw cycles, cell debris was removed by
centrifugation (12000 g, 30 min, 4 °C) and virus production was
determined by plaque assays on RD cells. The results were expressed
in PFU per μg of RNA. We checked that the viral progeny resulted from
transfectionwith viral RNA and not from residual infectious virions by
treating viral RNA solutions with RNAse A (100 μg/mL) for 20 min at
room temperature and using the products of this reaction to transfect
RD cells.
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Conﬂuent RD or HEp-2C cells were shaken for 30 min at 37 °C in
the presence of the virus at an MOI of approximately 50 PFU/cell.
DMEM supplemented with 2% FCS was added and the cells were
incubated for 2 h at 37 °C. The medium was then replaced by
methionine-free medium, in which the cells were incubated for
30min, before adding 600 μCi of 35S-methionine. Cells were lysed 24–
48 h after infection, frozen and thawed three times, and cell debris
was removed by centrifugation (12000 g, 30 min, 4 °C). Viral
preparations were clariﬁed and puriﬁed by CsCl density gradient
centrifugation as previously described (Blondel et al., 1983). Puriﬁed
viruses were desalted by gel ﬁltration on a PD-10 column (Pharmacia
Biotech) and stored at −70 °C until analysis. We then determined the
speciﬁc activity (CPM/PFU) of each puriﬁed radiolabeled virus. Cell
suspensions on ice were used to study virus adsorption; 1.5×106 to
5×106 cells were treated for 1 h at 37 °C with the anti-DAF mAb
BRIC216 (40 μg/mL), the anti-β2m mAb MCA1115 (5 μg/mL), the anti-
HLA mAbs (B9.12.1 (1:100), B1.23.2 (1:100) or W6/32 (10 μg/mL)) or
with the isotype controls (IgG1κ and IgG2aκ). The cells were then
infected with puriﬁed radiolabeled virus at an MOI of 10 PFU/cell in
DMEM supplemented with 2% FCS for 2 h on ice with gentle shaking.
The cells were then washed twice with 2% FCS in DMEM. Cell-
associated radioactivity was quantiﬁed by scintillation counting.
Percentages of bound viruses were calculated relative to the mock-
treated sample (DMEM without mAbs).
Sedimentation gradient analysis of viral and subviral particles
Suspensions of 1×107 RD cells were either mock-treated with
DMEMor treatedwith the anti-DAFmAb BRIC216 (40 μg/mL), the anti-
β2mmAbMCA1115 (5 μg/mL) or the anti-HLAmAb B9.12.1 (1:100) for
1 h at 37 °C in a shaker. The cells were pelleted by centrifugation
(1000 g, 5 min, 4 °C) and radiolabeled virus (MOI of 50 PFU/cell)
binding experiments were run for 2 h on ice. Unbound viruses were
removed by washing and infection was allowed to proceed in the
presence or absence of mAbs for 30 min (EV11/HU-1108/89) or 2 h
(EV7/Wallace) at 37 °C in a shaker. The cells were pelleted and the
supernatants containing the virus particles were harvested. The cells
were resuspended in 1ml DMEMand lysed byaddingNP-40 (0.2%ﬁnal
concentration, Calbiochem, La Jolla, California). Insoluble cell debris
was removed by centrifugation. Radiolabeled virus particles present in
supernatants or cell lysates were then sedimented by centrifugation
through 15–30% (w/v in PBS) sucrose gradients for 2 h at 287000 g and
4 °C in a Kontron TST 41.14 rotor. Radioactivity was quantiﬁed in the
fractions by scintillation counting. Similar binding experiments were
performed on CHO cells stably transfected with a gene encoding
human DAF or monochain HLA molecules.
Transfection of CHO cells and selection of stable transfectants
CHO-DAF/A9 cells were transfected with a plasmid encoding a
monochain Class I HLA molecule (β2m-HLA-A⁎2) in which the C-
terminus of human β2m was covalently linked to the N-terminus of a
chimeric human/mouse heavy chain (domains α1-α2 of HLA-A⁎0201,
linked to α3-transmembrane and intracytoplasmic domains of the
murine H-2Db molecule) (Firat et al., 2001; Pascolo et al., 1997). The
monochain genewas inserted into pBluescript II KS (−), which contains a
hygromycin resistance gene. Subconﬂuent CHO-DAF/A9 cells cultured in
35-mmdisheswere transfectedwith the FuGENE6 transfection reagent.
Hygromycin B (Invitrogen) was added to a ﬁnal concentration of 300 μg/
mL 24 h after transfection to select resistant cells. Transfected CHO cell
populations were enriched in hygromycin-resistant cells through two
cycles of selection of HLA-A positive clones, using an indirect technique
based on Dynabeads M-450 (DYNAL A. S, Oslo, Norway) (Deckert et al.,
1992). Hygromycin-resistant CHO cells were incubated with the anti-HLA mAb B9.12.1 on ice for 30 min. They were washed in Ham's F-12
medium supplemented with 2% FCS and incubated with Dynabeads
coated with rat anti-mouse IgG2a for 30 min on ice. The selected clones
were resuspended in Ham's F-12 medium supplemented with 10% FCS
and 300 μg/mL hygromycin B at conﬂuence. The expression of DAF, β2m
and HLA class I heavy chain on selected cells was monitored by ﬂow
cytometry, using the speciﬁc mAbs described above.
Detection of cell membrane protein expression by ﬂow cytometry
Surface expression of DAF, β2m and the HLA class I heavy chain
was analyzed by ﬂow cytometry in RD cells, leukocytes (Daudi, Raji, U-
937) and transfected CHO cells. Dispersed cells (106) were incubated
on ice with the appropriate mAbs (10 μg/mL except mAb B9.12.1
(1:100)) for 30 min in staining buffer (PBS (Eurobio) containing 1%
bovine serum albumin (wt/v), fraction V and 0.1% NaN3 (wt/v)). The
cells were thenwashedwith staining buffer, pelleted by centrifugation
at 900 g for 6 min, resuspended in 100 μl FITC-conjugated anti-mouse
antibody (diluted 1:100 in staining buffer), and incubated on ice for
30 min. The cells were again washed and pelleted, resuspended in
staining buffer, and 10000 events were analyzed for DAF, β2m and
HLA class I heavy chain expression with a FACScan cytometer (Becton
Dickinson, San Diego, California). Membrane protein expression was
quantiﬁed on leukocyte lines by determining mean ﬂuorescence
intensity (MFI) for each stain and calculating the MFI ratio (MFIR) by
dividing the MFI obtained with a speciﬁc antibody by the MFI
obtained with control IgG1κ (MOPC-21) or IgG2aκ (UPC-10). An
MFIR≥1.5 was considered positive.
Virus infectivity assays
Subconﬂuent cell monolayers were infected with EV11 strains
(Gregory or HU-1108/89) at an MOI of 1, 10 and 50 PFU/cell and
incubated in DMEM supplemented with 2% FCS at 37 °C for 48 h. For
suspension culture, Daudi, Raji and U-937 cells were counted, washed
once in Hank's balanced salt solution (Invitrogen), infected in RPMI
1640 supplemented with 2% FCS at an MOI of 10, 50 and 100 PFU/cell
and incubated at 37 °C for 6 or 48 h. Supernatants and cells were
harvested at various times after infection. The cells were subjected to
three freeze–thaw cycles, cell debris was removed, and the infectious
virus titer was determined by plaque assay on RD cells.
Detection of positive and negative strands of EV11 genome
Subconﬂuent CHO-Bill, CHO-DAF/A9, CHO-DAF-β2m-HLA-A⁎2 and
RD cells were infected with EV11 (HU-1108/89) at an MOI of 10 PFU/
cell and incubated for 30min at 37 °C. The inoculumwas removed and
the cells were washed three times with PBS, covered with 2 ml of
medium supplemented with 2% FCS and incubated at 37 °C in an
atmosphere containing 5% CO2. Three and 6 h later the cells were
washed three timeswith PBS and total RNAwas extractedwith RNable
reagent (Eurobio). The RNA pellet was dissolved in 20 μl of DEPC-
treated water (Invitrogen), and the absorbance of the resulting
solution was determined at 260 nm. Both positive and negative
strands of EV11 RNA were sought by RT-PCR. Total RNA (1 μg) was
reverse transcribed with the EUC2a primer 5′-TCCAAATGCCGTATT-
GAACC-3′ (10 pmol) or the EUG4a primer 5′-TCCACTATCACCACD-
CAGGA-3′ (50 pmol) for positive and negative strand ampliﬁcation,
respectively. Reverse transcriptionwas performed as described above,
except that the cDNA products were eluted in 30 μl of 10 mM Tris-Cl
pH 8.5 during puriﬁcation with the QIAquick PCR Puriﬁcation kit
(Qiagen). Samples were treated with RNAse A solution (1 μg/μL) for
20 min at 37 °C. The cDNA product (3 μl) was added to a PCR mixture
containing 67mM Tris–HCl pH 8.8,16 mM (NH4)2SO4, 0.01% Tween 20,
2 mM MgCl2, 10 mM dNTPs, 2 U of Taq DNA polymerase (EurobioTaq,
Eurobio) and 10 pmol of the PCR primers for ampliﬁcation of the 376-bp
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achieved by 29 cycles of denaturation at 95 °C for 20 s, annealing at
45 °C for 1 min and elongation at 72 °C for 1 min, followed by a ﬁnal
cycle of denaturation at 95 °C for 20 s, annealing at 45 °C for 1 min and
elongation at 72 °C for 10 min. Ampliﬁcation products (5 μl) were
analyzed by electrophoresis in 1.5% agarose gels. Gels were stained with
ethidium bromide and viewed under UV transillumination.
Detection of intracellular viruses by ﬂow cytometry
The procedure for ﬁxing and staining infected cells for ﬂow
cytometry is described elsewhere (Lafﬁn and Lehman,1994; McSharry
et al., 1990). Brieﬂy, uninfected cells and cells infected with EV11 (HU-
1108/89 strain, MOI 10 PFU/cell) were treated with trypsin 6 h after
infection, washed once in a solution containing 10% heat-inactivated
goat serum (Invitrogen), 0.002% Triton X-100, and 0.1% NaN3 in PBS,
and ﬁxed by adding cold methanol to a ﬁnal concentration of 90%. The
ﬁxed cells were counted in a hemocytometer and stored at −70 °C at a
density of 106 cells per ml in 90% methanol. The ﬁxative solution was
removed and the cells were washed once in PBS and resuspended in
polyclonal rabbit anti-EV11 (HU-1108/89) serum diluted (1:100) in the
same washing solution then incubated at 4 °C for 1 h. The cells were
pelleted by centrifugation, washed twice, resuspended in FITC-
conjugated goat anti-rabbit antibody diluted (1:100) in the washing
solution, and incubated at 4 °C for 45 min. The cells were washed
twice, pelleted by centrifugation and resuspended in staining buffer.
Ten thousand events were then analyzed for virus detection with a
FACScan cytometer (Becton Dickinson).
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